|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients developing EGFR T790M resistance mutations.
|
28620690 |
2017 |
|
rs397517132
|
|
|
0.050 |
GeneticVariation |
BEFREE |
V599E BRAF mutation was uncommon in Japanese lung cancer.
|
16376942 |
2006 |
|
rs727504256
|
|
|
0.010 |
GeneticVariation |
BEFREE |
E709K and Ins770G as well as L858R appear to be functional mutations based on the use of Ba/F3 cells.
|
19726454 |
2009 |
|
rs146795390
|
|
|
0.030 |
GeneticVariation |
BEFREE |
V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.
|
25057940 |
2014 |
|
rs121913465
|
|
|
0.010 |
GeneticVariation |
BEFREE |
S768I Mutation in EGFR in Patients with Lung Cancer.
|
27211795 |
2016 |
|
rs397517108
|
|
|
0.010 |
GeneticVariation |
BEFREE |
S768I Mutation in EGFR in Patients with Lung Cancer.
|
27211795 |
2016 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer.
|
29963252 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A 79-year-old woman had disease progression during third-line treatment with osimertinib for an EGFR L858R/T790M-mutant lung cancer.
|
31254668 |
2019 |
|
rs146795390
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
|
23380224 |
2013 |
|
rs1420841957
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer.
|
18478265 |
2008 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
|
24453288 |
2014 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
|
24453288 |
2014 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
|
24453288 |
2014 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
|
24453288 |
2014 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
|
30276451 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A preexisting EGFR T790M mutation was noted in 25% of patients with EGFR-mutant lung cancer.
|
24737599 |
2014 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of 50 lung cancer patients' tumor tissues were analyzed, and two frequent mutations associated with therapeutic efficiency of lung cancer were identified, including deletion of exon 19 (8/50) and L858R point mutation in exon 21 (12/50).
|
22901298 |
2012 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of 50 lung cancer patients' tumor tissues were analyzed, and two frequent mutations associated with therapeutic efficiency of lung cancer were identified, including deletion of exon 19 (8/50) and L858R point mutation in exon 21 (12/50).
|
22901298 |
2012 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of 50 lung cancer patients' tumor tissues were analyzed, and two frequent mutations associated with therapeutic efficiency of lung cancer were identified, including deletion of exon 19 (8/50) and L858R point mutation in exon 21 (12/50).
|
22901298 |
2012 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.
|
27573423 |
2016 |
|
rs397517132
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer.
|
29348459 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.
|
21135146 |
2011 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although afatinib inhibited the growth of lung cancer cells with low T790M allele frequencies in preclinical studies, this could not be translated into clinical efficacy in terms of lowering the rate or delaying the time of T790M acquisition.
|
31030101 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although this class of mutant-selective EGFR inhibitors is effective clinically in lung cancer patients harboring EGFR(T790M), prior preclinical studies demonstrate that acquired resistance can occur through genomic alterations that activate ERK1/2 signaling.
|
26036643 |
2015 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Amplification-refractory mutation system PCR has been used for the analysis of ctDNA to detect resistance-causing mutations in the epidermal growth factor receptor gene (eg, EGFR T790M) in lung cancer patients.
|
28732213 |
2017 |